ReviewTherapeutic advances in gastroenterology2026
Advancements in targeted therapy for gastric cancer.
Review in Therapeutic advances in gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Composite Histopathologic Invasion Score Predicts Lymph Node Metastasis in Gastric Cancer.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) ranks among the most prevalent malignancies of the gastrointestinal system. For patients with advanced-stage disease undergoing surgical resection, postoperative 5-year survival rates remain critically low, typically below 20%. Contemporary therapeutic strategies encompass surgical intervention, cytotoxic chemotherapy, immune checkpoint blockade, and molecularly-targeted agents. Targeted therapeutics exert their effects by exploiting molecular vulnerabilities such as human epidermal growth factor receptor-2, Claudin 18.2, vascular endothelial growth factor/vascular endothelial growth factor receptor, fibroblast growth factor receptor 2, and N6-methyladenosine modification pathways, thereby suppressing tumor proliferation and offering improved clinical outcomes for advanced GC. These agents demonstrate significant potential in extending overall survival durations, underscoring their translational value and substantial research implications. This comprehensive review delineates recent advancements in GC-targeted therapies to inform precision oncology paradigms and guide future drug discovery initiatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.